BIOVENTIX PLC

Director's Dealing • Apr 17, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

BIOVENTIX PLC - Director Dealing

PR Newswire

London, April 17

                             Bioventix plc                        ("Bioventix" or the "Company")                               Director dealingBioventix plc (AIM: BVXP) was notified on 16 April 2015 that on the same day,due to institutional investor demand, the following director dealt in theordinary shares of 5 pence each ("Ordinary Shares") in the Company:Name        Position     Type of      Number of    Price    Ordinary  Percentage                         transaction   Ordinary      per  shares and of Ordinary                                         Shares Ordinary      voting  Shares and                                                   Share rights held      voting                                                 (pence)   following rights held                                                                 the   following                                                         transaction         the                                                                     transactionPeter       Chief        Disposal      100,000\*      800     661,176       13.1%Harrison    Executive\*    3,000 of which were held in the name of his wifeFor further information please contact:Bioventix plc              Chief Executive Officer    Tel: 01252 728 001Peter HarrisonfinnCap Ltd                Corporate Finance          Tel: 020 7220 0500Geoff Nash/Simon Hicks     Corporate BrokingSteve NorcrossAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.